Saturday 17 October 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.
16.28
1.02
−5.90%
Follow RLAY
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 3 | 4 | 2 | 5 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | 0.00 | 964.56 | 1,222.30 | 56.91 | 16.66 | 57.24 |
Altman Z-Score |
— | — | — | 29.39 | 14.72 | 5.53 | 6.10 | 0.63 | 10.99 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 26.02 | 9.80 | 7.41 | 5.96 | 5.07 | 2.96 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (12.50) | (2.69) | — | — | — |
P/Operating CF |
— | — | — | (50.22) | (73.58) | (29.57) | (16.30) | (10.17) | (32.36) |
P/B ratio |
— | — | — | 2.32 | 3.25 | 1.78 | 1.93 | 0.76 | 2.56 |
Price to Tangible BV |
— | — | — | 2.32 | 3.26 | 1.78 | 1.94 | 0.76 | 2.57 |
EV/Sales |
— | — | — | 0.00 | 648.26 | 498.97 | 27.55 | (5.45) | 35.37 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | 0.00 |
EV/Operating CF |
— | — | — | (10.67) | (26.39) | (3.00) | (2.34) | 0.77 | (3.81) |
EV/FCF |
— | — | — | (10.47) | (25.21) | (2.89) | (2.31) | 0.77 | (3.80) |
Quick Ratio |
— | 60.29 | 29.69 | 55.24 | 39.41 | 15.68 | 24.78 | 15.40 | 21.68 |
Current Ratio |
— | 60.57 | 30.08 | 56.49 | 40.14 | 16.00 | 25.44 | 15.95 | 22.61 |
Net Debt/EBITDA |
— | 8.84 | 4.25 | 12.88 | 2.67 | 3.40 | 1.98 | 2.06 | 1.84 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.14 | 0.00 | 0.00 | 0.03 | 0.01 | 0.02 |
Operating CF/Net income |
— | 0.90 | 0.88 | 0.45 | 0.20 | 0.79 | 0.88 | 0.74 | 0.85 |
Capex/Depreciation |
— | 0.00 | (22.81) | (0.62) | (0.58) | (1.71) | 0.75 | 0.29 | (0.45) |
Interest Coverage |
— | (89.65) | — | — | — | — | — | — | — |
| — | 33.53% | 51.68% | (78.99%) | (43.81%) | (31.44%) | (40.18%) | (44.15%) | (41.12%) | |
| — | (22.74%) | (18.32%) | (38.60%) | (40.25%) | (27.56%) | (35.19%) | (39.38%) | (37.05%) | |
ROIC |
— | 0.00% | 0.00% | (40.91%) | 0.00% | 0.00% | (12,160.29%) | 0.00% | (1,508.62%) |
Return on Tangible Assets |
— | (11.59%) | (21.11%) | (30.18%) | (37.96%) | (30.03%) | (45.55%) | (44.18%) | (49.87%) |
Average Days of Receivables |
— | — | — | 331.20 | 48.56 | 80.88 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 120.82% | 5,699.90% | 17,838.88% | 1,291.86% | 3,188.66% | 1,702.27% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 46.69% | 1,894.55% | 4,777.55% | 293.39% | 765.38% | 369.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 38.67% | 1,599.67% | 4,065.03% | 336.77% | 940.73% | 406.51% |
Graham Net Nets |
— | — | — | 0.41 | 0.30 | 0.52 | 0.47 | 1.22 | 0.36 |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (2.95%) | (12.54%) | (17.29%) | (23.61%) | (58.01%) | (19.15%) |
Free Cash Flow Yield |
— | — | — | (5.90%) | (2.67%) | (14.13%) | (20.94%) | (42.66%) | (16.25%) |
Revenue per Share |
— | 0.00 | 0.00 | 1.94 | 0.03 | 0.01 | 0.21 | 0.07 | 0.09 |
Operating CF per Share |
— | (0.49) | (19.16) | (2.40) | (0.78) | (2.04) | (2.45) | (1.74) | (1.37) |
Capex per Share |
— | 0.00 | (2.31) | (0.05) | (0.04) | (0.08) | (0.03) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (0.49) | (21.48) | (2.45) | (0.82) | (2.13) | (2.48) | (1.76) | (1.37) |
Cash per Share |
— | 4.70 | 103.11 | 15.91 | 10.07 | 8.90 | 6.12 | 5.47 | 3.23 |
Shareholders Equity per Share |
— | 4.68 | (52.29) | 17.91 | 9.44 | 8.47 | 6.13 | 5.44 | 3.30 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 4.68 | (52.29) | 17.91 | 9.44 | 8.47 | 6.13 | 5.44 | 3.30 |
Free Cash Flow |
— | (44.13) | (74.11) | (104.42) | (77.88) | (238.55) | (304.44) | (251.12) | (235.86) |
Working Capital |
— | 417.00 | 348.55 | 756.47 | 951.92 | 955.80 | 739.83 | 758.48 | 552.70 |
Capital Expenditures |
— | (1.69) | (7.98) | (1.93) | (3.47) | (9.06) | (4.13) | (2.02) | (0.41) |
Net Current Asset Value |
— | 417.00 | (212.97) | 733.56 | 865.61 | 869.95 | 678.13 | 715.70 | 524.01 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.52 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.02 | 1.15 | 6.56 | 0.16 | 0.20 | 0.03 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.54 | 0.04 | 0.50 | 0.91 | 0.46 | (0.50) | (1.16) | 0.53 |
Cash ROIC |
— | (5.24%) | (42.26%) | (7.24%) | (4.20%) | (12.24%) | (20.27%) | (16.11%) | (21.03%) |
Accounts Receivable Turnover |
— | — | — | 1.88 | 0.08 | 3.90 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 847.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 44.00 | 37.70 | 0.35 | — | — | — |
Average Payables |
— | 6.00 | 6.00 | 6.67 | 7.31 | 9.43 | 9.89 | 11.65 | 10.90 |
Average Assets |
— | 214.50 | 411.03 | 596.45 | 904.14 | 1,054.11 | 971.88 | 857.64 | 746.31 |
Average Common Equity |
— | (145.50) | (145.72) | 291.43 | 830.55 | 924.01 | 851.11 | 764.90 | 672.43 |
Columns are period end dates